AREDYLD syndrome
AREDYLD syndrome is a rare genetic disorder characterized by a combination of anemia, reticulocytosis, and dyskeratosis. The name AREDYLD is an acronym derived from these primary symptoms: Anemia, Reticulocytosis, and Dyskeratosis.
Presentation[edit | edit source]
Individuals with AREDYLD syndrome typically present with symptoms related to anemia, such as fatigue, pallor, and shortness of breath. The reticulocytosis indicates an increased number of reticulocytes in the blood, which are immature red blood cells. Dyskeratosis refers to abnormal keratinization of the skin, leading to skin abnormalities such as hyperpigmentation, nail dystrophy, and oral leukoplakia.
Genetics[edit | edit source]
AREDYLD syndrome is believed to be inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the defective gene, one from each parent, to manifest the disease. The specific gene or genes involved in AREDYLD syndrome have not been definitively identified.
Diagnosis[edit | edit source]
Diagnosis of AREDYLD syndrome is based on clinical evaluation, detailed patient history, and laboratory tests. Blood tests typically reveal anemia and reticulocytosis. A skin biopsy may be performed to confirm dyskeratosis. Genetic testing can be used to identify mutations associated with the syndrome.
Treatment[edit | edit source]
There is no cure for AREDYLD syndrome, and treatment is primarily supportive. Management of anemia may include blood transfusions and iron supplementation. Skin abnormalities may be treated with topical medications and other dermatological interventions. Regular monitoring and supportive care are essential to manage the symptoms and improve the quality of life for affected individuals.
Prognosis[edit | edit source]
The prognosis for individuals with AREDYLD syndrome varies depending on the severity of the symptoms and the effectiveness of the supportive treatments. Early diagnosis and comprehensive management can improve outcomes and quality of life.
See also[edit | edit source]
References[edit | edit source]
External links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD